prazosin has been researched along with Psychomotor Agitation in 4 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prazosin was well tolerated and improved behavioral symptoms in patients with agitation/aggression in AD." | 9.14 | Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. ( Hart, KL; Hoff, DJ; McFall, YH; Peskind, ER; Raskind, MA; Rohde, K; Shofer, JB; Wang, LY, 2009) |
| "Prazosin was well tolerated and improved behavioral symptoms in patients with agitation/aggression in AD." | 5.14 | Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. ( Hart, KL; Hoff, DJ; McFall, YH; Peskind, ER; Raskind, MA; Rohde, K; Shofer, JB; Wang, LY, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luján, MA | 1 |
| Colomar, L | 1 |
| Tarragón, E | 1 |
| López-Cruz, L | 1 |
| Pastor, R | 1 |
| Font, L | 1 |
| Wang, LY | 1 |
| Shofer, JB | 1 |
| Rohde, K | 1 |
| Hart, KL | 1 |
| Hoff, DJ | 1 |
| McFall, YH | 1 |
| Raskind, MA | 1 |
| Peskind, ER | 1 |
| Vanderschuren, LJ | 1 |
| Beemster, P | 1 |
| Schoffelmeer, AN | 1 |
| Sharp, SI | 1 |
| Ballard, CG | 1 |
| Chen, CP | 1 |
| Francis, PT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alzheimer's in Long-Term Care--Treatment for Agitation[NCT00161473] | 24 participants (Actual) | Interventional | 2001-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Brief Psychiatric Rating Scale (BPRS) is an 18-item scale that rates psychiatric symptoms. Each item ranges from 1 to 7. Therefore, the Brief Psychiatric Rating Scale total score ranges from a minimum of 0 to a maximum of 126, where 126 indicates higher levels of behavioral symptoms.~A change Brief Psychiatric Rating Scale score that is a negative number (that is, a Brief Psychiatric Rating Scale score decrease), indicates behavioral improvement." (NCT00161473)
Timeframe: Weeks 2, 4, 6, and 8 (change from Baseline)
| Intervention | units on a scale (Mean) |
|---|---|
| Prazosin | -9 |
| Placebo | -3 |
"The Neuropsychiatric Inventory (NPI) is a 12-item scale that assesses the frequency and severity of behavioral symptoms in patients with dementia. Each Neuropsychiatric Inventory item ranges from 0 to 12. Therefore the Neuropsychiatric Inventory total score has a minimum total value of 0 and maximum 144, where 144 indicates higher levels of behavioral symptoms.~A change in Neuropsychiatric Inventory total score that is a negative number (that is, an Neuropsychiatric Inventory score decrease), indicates behavioral improvement." (NCT00161473)
Timeframe: Weeks 2, 4, 6, and 8 (change from Baseline)
| Intervention | units on a scale (Mean) |
|---|---|
| Prazosin | -19 |
| Placebo | -2 |
"The Clinical Global Impression of Change (CGIC) is a 7 point scale, where 1 indicates markedly improved, 4 indicates no change, and 7 indicates markedly worse." (NCT00161473)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Prazosin | 2.6 |
| Placebo | 4.5 |
This measure reflects the length of time participants remained in the study. There were 6 behavioral assessment visits included in the protocol. (NCT00161473)
Timeframe: Last behavioral assessment (Baseline, Weeks 1, 2, 4, 6, or 8)
| Intervention | number of visits (Mean) |
|---|---|
| Prazosin | 4.8 |
| Placebo | 4.5 |
1 trial available for prazosin and Psychomotor Agitation
| Article | Year |
|---|---|
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Behavioral Sym | 2009 |
3 other studies available for prazosin and Psychomotor Agitation
| Article | Year |
|---|---|
Drug-free and context-dependent locomotor hyperactivity in DBA/2 J mice previously treated with repeated cocaine: Relationship with behavioral sensitization and role of noradrenergic receptors.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Association; Behavior | 2019 |
On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization.
Topics: Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Clonidine; Cocaine; Cocai | 2003 |
Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Binding Sites; Cell Count; Cerebellum; Frontal | 2007 |